Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Prediction of Therapeutic Potential of CD19 CAR-T Cells for LBCL By Histone Mark Analyses of Core Epigenetic Programming

Salvatore Fiorenza, Yue Cao, Ye Zheng, Janaki Purushe, Tamara Bock, Erik L Kimble, Derek Janssens, Delaney Kirchmeier, Alexandre V. Vinaud Hirayama, Jordan Gauthier, David G. Maloney, Stanley R. Riddell, Akira Nguyen-Shaw, Steven Henikoff, Jean Yang, Cameron J. Turtle

Blood (2024) 144 (Supplement 1): 2028.

https://doi.org/10.1182/blood-2024-200589

Published: 2024

Journal Articles

Phase 2 Study of Anakinra to Prevent CRS and Neurotoxicity after Treatment with Lisocabtagene Maraleucel: Planned Interim Analysis

Blood (2023) 142 (Supplement 1): 6848.

https://doi.org/10.1182/blood-2023-172695

Published: 2023

Journal Articles

Machine Learning-Based Time-Series Clustering Identifies Archetypal Trajectories of Hematotoxicity after CAR T-Cell Therapy

Blood (2023) 142 (Supplement 1): 2143.

https://doi.org/10.1182/blood-2023-174106

Published: 2023

Journal Articles

Day +3/Day 0 Ferritin Ratio: A Simple Point-of-Care Index Predictive of Severe Immune Effector Cell-Associated Neurotoxicity Syndrome after CD19 CAR T-Cell Therapy

Blood (2023) 142 (Supplement 1): 3495.

https://doi.org/10.1182/blood-2023-182597

Published: 2023

Journal Articles

Phase I/II Study to Evaluate the Safety, Feasibility, and Efficacy of FP-1201 (Intravenous Interferon-Beta-1a) to Prevent Toxicities after CD19-Directed CAR T-Cell Therapy: Trial in Progress

Emily C Liang, Erik L Kimble, Aya Albittar, Jennifer J. Huang, Andrew J Portuguese, Aiko Torkelson, Delaney Kirchmeier, Abigail Chutnik, Barbara Pender, Sylvain Simon, Tony Chour, Evan W. Newell, Rahul Banerjee, David G Maloney, Alexander Spicer, Juho Jalkanen, Alexandre V Hirayama, Jordan Gauthier

Blood (2023) 142 (Supplement 1): 4860.

https://doi.org/10.1182/blood-2023-173152

Published: 2023

Journal Articles

Histone Methylation Mark Analyses Distinguish Carts Manufactured from Distinct Sources and Uncover Novel Transcription Factors Associated with In Vivo Function of Carts after Infusion into DLBCL Patients That Are Not Identified By RNA-Seq

Salvatore Fiorenza, Ye Zheng, Jay Sarthy, Alyssa Sheih, Erik L Kimble, Delaney Kirchmeier, Derek Janssens, Tinh-Doan Phi, Jordan Gauthier, Alexandre V Hirayama, Qian Wu, Raphael Gottardo, Stanley R. Riddell, David G Maloney, Steven Henikoff, Cameron J. Turtle

Blood (2023) 142 (Supplement 1): 3454.

https://doi.org/10.1182/blood-2023-188269

Published: 2023

Journal Articles

Phase 2 Study of CD19 CAR T Cells with a Fully Human Binder for Large B-Cell Lymphoma in Relapse or Progression after a Murine Binder-Bearing CD19 CAR T-Cell Therapy

Blood (2023) 142 (Supplement 1): 6860.

https://doi.org/10.1182/blood-2023-181273

Published: 2023

NARROW

Prediction of Therapeutic Potential of CD19 CAR-T Cells for LBCL By Histone Mark Analyses of Core Epigenetic Programming

Phase 2 Study of Anakinra to Prevent CRS and Neurotoxicity after Treatment with Lisocabtagene Maraleucel: Planned Interim Analysis

Machine Learning-Based Time-Series Clustering Identifies Archetypal Trajectories of Hematotoxicity after CAR T-Cell Therapy

Day +3/Day 0 Ferritin Ratio: A Simple Point-of-Care Index Predictive of Severe Immune Effector Cell-Associated Neurotoxicity Syndrome after CD19 CAR T-Cell Therapy

Phase I/II Study to Evaluate the Safety, Feasibility, and Efficacy of FP-1201 (Intravenous Interferon-Beta-1a) to Prevent Toxicities after CD19-Directed CAR T-Cell Therapy: Trial in Progress

Histone Methylation Mark Analyses Distinguish Carts Manufactured from Distinct Sources and Uncover Novel Transcription Factors Associated with In Vivo Function of Carts after Infusion into DLBCL Patients That Are Not Identified By RNA-Seq

Phase 2 Study of CD19 CAR T Cells with a Fully Human Binder for Large B-Cell Lymphoma in Relapse or Progression after a Murine Binder-Bearing CD19 CAR T-Cell Therapy

Email alerts

ASH Publications

American Society of Hematology

Prediction of Therapeutic Potential of CD19 CAR-T Cells for LBCL By Histone Mark Analyses of Core Epigenetic Programming

Phase 2 Study of Anakinra to Prevent CRS and Neurotoxicity after Treatment with Lisocabtagene Maraleucel: Planned Interim Analysis

Machine Learning-Based Time-Series Clustering Identifies Archetypal Trajectories of Hematotoxicity after CAR T-Cell Therapy

Day +3/Day 0 Ferritin Ratio: A Simple Point-of-Care Index Predictive of Severe Immune Effector Cell-Associated Neurotoxicity Syndrome after CD19 CAR T-Cell Therapy

Phase I/II Study to Evaluate the Safety, Feasibility, and Efficacy of FP-1201 (Intravenous Interferon-Beta-1a) to Prevent Toxicities after CD19-Directed CAR T-Cell Therapy: Trial in Progress

Histone Methylation Mark Analyses Distinguish Carts Manufactured from Distinct Sources and Uncover Novel Transcription Factors Associated with In Vivo Function of Carts after Infusion into DLBCL Patients That Are Not Identified By RNA-Seq

Phase 2 Study of CD19 CAR T Cells with a Fully Human Binder for Large B-Cell Lymphoma in Relapse or Progression after a Murine Binder-Bearing CD19 CAR T-Cell Therapy

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only